Endogena Therapeutics is a clinical-stage biotech company focused on developing endogenous regenerative medicines aimed at repairing and regenerating tissues and organs. The company seeks to transform the treatment of degenerative conditions associated with aging and genetic disorders by regulating endogenous adult stem and progenitor cells through small molecules. Endogena's innovative approach combines advancements in stem cell biology with artificial intelligence and expertise in drug design, targeting conditions such as retinitis pigmentosa and geographic atrophy. By offering a pipeline of potential therapies, Endogena aims to provide significant contributions to the healthcare industry in addressing various degenerative diseases.
DiA Imaging Analysis Ltd. specializes in developing AI-powered ultrasound analysis technology to enhance cardiac function diagnosis through echocardiographic examinations. The company offers a range of automated solutions, including LVivo EF for ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain, which assesses myocardial strain as an early indicator of reduced left ventricular function. Additional products include LVivo SWM for segmental wall motion analysis, LVivo SAX for coronary heart disease detection, and LVivo Mobile for mobile ultrasound analysis. Founded in 2009 and headquartered in Beersheba, Israel, DiA addresses significant challenges in ultrasound imaging by providing tools that facilitate the acquisition of optimal images and their subsequent analysis. The company’s technology is designed to integrate seamlessly into existing ultrasound devices and healthcare IT systems, making advanced diagnostics more accessible. With FDA and CE clearances for its cardiac toolbox, DiA serves a global user base and generates revenue through its innovative solutions.
Acepodia is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer treatment using its proprietary Antibody-Cell Conjugation platform technology. The company aims to enhance immune cells with antibodies to create effective immunotherapeutic strategies against various types of cancer. Acepodia is dedicated to expanding its research, clinical development, and manufacturing capabilities, maintaining a broad pipeline portfolio that targets multiple cancer types. Through its commitment to creating first-in-class therapies, Acepodia strives to make these advanced treatments widely accessible to patients.
Endogena Therapeutics is a clinical-stage biotech company focused on developing endogenous regenerative medicines aimed at repairing and regenerating tissues and organs. The company seeks to transform the treatment of degenerative conditions associated with aging and genetic disorders by regulating endogenous adult stem and progenitor cells through small molecules. Endogena's innovative approach combines advancements in stem cell biology with artificial intelligence and expertise in drug design, targeting conditions such as retinitis pigmentosa and geographic atrophy. By offering a pipeline of potential therapies, Endogena aims to provide significant contributions to the healthcare industry in addressing various degenerative diseases.
Aegle Therapeutics Corporation is a biotechnology company focused on developing innovative therapies using extracellular vesicles (EVs) derived from allogeneic bone marrow-derived mesenchymal stem cells. Founded in 2019 and headquartered in Arlington, Massachusetts, with an additional office in Miami, Florida, Aegle's primary aim is to address dermatological conditions, particularly dystrophic epidermolysis bullosa, a rare pediatric skin disorder characterized by severe blistering. The company's platform technology harnesses the regenerative properties of stem cells through a cell-free approach, which has the potential to enhance healing, reduce scarring, and improve the overall appearance of affected skin. Aegle's investigational new drug application for treating dystrophic epidermolysis bullosa has been approved by the FDA, and the company anticipates beginning clinical trials.
InformAI, LLC provides business analytics and artificial intelligence solutions for healthcare industry. The company offers solutions and services which that speed up medical diagnosis and radiologist productivity. It provides paranasal sinus classifier, brain cancer classifier, surgical risk predictors, and patient outcome predictors. The company was founded in 2017 and is based in Houston, Texas.
TARA Biosystems, Inc. is a biotechnology company focused on developing organ-on-a-chip technology, specifically human cardiac tissue models, to enhance drug discovery and safety assessments. Founded in 2014 and based in the United States, the company utilizes stem cell-derived cardiac tissue that mimics adult physiological conditions, enabling precise measurement of cardiac functionality. This innovative platform aims to facilitate the faster and safer development of new therapies by providing predictive in vitro models that can assess the effects of drug compounds on heart function without the need for human testing. Through its advanced technology, TARA Biosystems seeks to improve the health of patients by enabling more reliable assessments of cardiac drug efficacy and safety.
1World Online, Inc. operates a consumer intelligence platform that facilitates the creation of polls, quizzes, surveys, and trivia to enhance revenue and reader engagement. The platform caters to publishers, advertisers, and users by offering a unique, blockchain-powered model that integrates data and advertising. It aims to improve audience understanding, profiling, and monetization, while also providing editors and journalists access to timely news content for better story targeting and reader relationship enhancement. Founded in 2011, 1World Online is headquartered in Redwood City, California, with additional offices in various locations including San Jose, Boston, India, Mexico, Latin America, Europe, Japan, Ukraine, Singapore, and China.
Aegle Therapeutics Corporation is a biotechnology company focused on developing innovative therapies using extracellular vesicles (EVs) derived from allogeneic bone marrow-derived mesenchymal stem cells. Founded in 2019 and headquartered in Arlington, Massachusetts, with an additional office in Miami, Florida, Aegle's primary aim is to address dermatological conditions, particularly dystrophic epidermolysis bullosa, a rare pediatric skin disorder characterized by severe blistering. The company's platform technology harnesses the regenerative properties of stem cells through a cell-free approach, which has the potential to enhance healing, reduce scarring, and improve the overall appearance of affected skin. Aegle's investigational new drug application for treating dystrophic epidermolysis bullosa has been approved by the FDA, and the company anticipates beginning clinical trials.
Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics that target Glycogen Synthase Kinase-3ß (GSK-3ß) for Alzheimer’s disease, bipolar disorder, diabetes mellitus type II, inflammatory conditions, and cancer. It develops compounds for combination use in high impact carcinomas, including glioblastoma, ovarian, breast, and pancreatic cancers. Actuate Therapeutics, Inc. was formerly known as Apotheca Therapeutics, Inc. The company was incorporated in 2015 and is based in Fort Worth, Texas with an additional office in Dublin, Ireland.
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology. Its mission is to improve clinical outcomes and the quality of life for all cancer patients and to be at the forefront of turning cancer into a curable disease. The company has harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells.
Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics that target Glycogen Synthase Kinase-3ß (GSK-3ß) for Alzheimer’s disease, bipolar disorder, diabetes mellitus type II, inflammatory conditions, and cancer. It develops compounds for combination use in high impact carcinomas, including glioblastoma, ovarian, breast, and pancreatic cancers. Actuate Therapeutics, Inc. was formerly known as Apotheca Therapeutics, Inc. The company was incorporated in 2015 and is based in Fort Worth, Texas with an additional office in Dublin, Ireland.
Immusoft Corporation is a biotechnology company based in Seattle, Washington, focused on developing autologous cell therapies for various human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009, the company modifies a patient's immune cells, specifically B cells, to create miniature drug factories that produce gene-encoded medicines, or biologics. By reprogramming these cells, Immusoft's technology enables the in vivo delivery of therapeutics that can replace missing or defective enzymes and proteins. The core ISP technology was initially developed at the California Institute of Technology and is exclusively licensed to Immusoft. This innovative approach aims to improve treatments for rare and infectious diseases by harnessing the body's own immune system.
Savonix, Inc. is a San Francisco-based company that specializes in developing a digital neuro-cognitive assessment and brain health platform. Founded in 2014, its flagship product, Savonix Mobile, allows users to perform clinically recognized cognitive assessments on mobile devices. This platform provides accessible tests covering various cognitive domains, such as memory and implicit learning, which are guided by virtual clinicians. Savonix's assessments are designed to help healthcare providers, researchers, and insurers understand cognitive risks, including those related to dementia, and to inform treatment planning and diagnosis. The company has established strategic partnerships with notable institutions, including New York University and several biotech firms. Unique features of the platform include a 3D gaming component that generates additional cognitive insights without requiring separate tests, enhancing the understanding of cognitive function in aging populations. Savonix aims to deliver an affordable, scalable, and actionable solution for monitoring cognitive health, making it a leader in the field of digital cognitive assessment.
Savonix, Inc. is a San Francisco-based company that specializes in developing a digital neuro-cognitive assessment and brain health platform. Founded in 2014, its flagship product, Savonix Mobile, allows users to perform clinically recognized cognitive assessments on mobile devices. This platform provides accessible tests covering various cognitive domains, such as memory and implicit learning, which are guided by virtual clinicians. Savonix's assessments are designed to help healthcare providers, researchers, and insurers understand cognitive risks, including those related to dementia, and to inform treatment planning and diagnosis. The company has established strategic partnerships with notable institutions, including New York University and several biotech firms. Unique features of the platform include a 3D gaming component that generates additional cognitive insights without requiring separate tests, enhancing the understanding of cognitive function in aging populations. Savonix aims to deliver an affordable, scalable, and actionable solution for monitoring cognitive health, making it a leader in the field of digital cognitive assessment.
Touchence, Inc., founded in 2011 and headquartered in Taito, Japan, specializes in the development, manufacturing, and marketing of advanced tactile sensors. Originating from research at the University of Tokyo, the company utilizes cutting-edge technology to create sensors made from a foam-like material that can be touched, pinched, and respond to interaction and pressure in three-dimensional space. These innovative sensors are designed to enhance the functionality of robots and artificial intelligence systems, allowing manufacturers to integrate soft, responsive surfaces into their products. This integration aims to make human-robot interaction more natural and intuitive, thus improving the overall user experience.
DiA Imaging Analysis Ltd. specializes in developing AI-powered ultrasound analysis technology to enhance cardiac function diagnosis through echocardiographic examinations. The company offers a range of automated solutions, including LVivo EF for ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain, which assesses myocardial strain as an early indicator of reduced left ventricular function. Additional products include LVivo SWM for segmental wall motion analysis, LVivo SAX for coronary heart disease detection, and LVivo Mobile for mobile ultrasound analysis. Founded in 2009 and headquartered in Beersheba, Israel, DiA addresses significant challenges in ultrasound imaging by providing tools that facilitate the acquisition of optimal images and their subsequent analysis. The company’s technology is designed to integrate seamlessly into existing ultrasound devices and healthcare IT systems, making advanced diagnostics more accessible. With FDA and CE clearances for its cardiac toolbox, DiA serves a global user base and generates revenue through its innovative solutions.
ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.
ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.
ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.
1World Online, Inc. operates a consumer intelligence platform that facilitates the creation of polls, quizzes, surveys, and trivia to enhance revenue and reader engagement. The platform caters to publishers, advertisers, and users by offering a unique, blockchain-powered model that integrates data and advertising. It aims to improve audience understanding, profiling, and monetization, while also providing editors and journalists access to timely news content for better story targeting and reader relationship enhancement. Founded in 2011, 1World Online is headquartered in Redwood City, California, with additional offices in various locations including San Jose, Boston, India, Mexico, Latin America, Europe, Japan, Ukraine, Singapore, and China.
MeeVee offers a personalized online TV guide that allows users to curate their viewing experience based on their favorite actors, genres, or specific interests. By selecting preferences, users receive tailored recommendations for upcoming programming, which the guide continuously updates until interests are modified. The platform provides detailed information, including local television schedules, show summaries, episode trailers, ratings, and cast details, all at no cost. Additionally, MeeVee features a widget, known as the MeeVee Guide, which can be integrated into other websites, enabling visitors to view personalized TV listings. This service aims to simplify how individuals discover and enjoy television content, moving away from traditional universal grids to a more customized viewing experience.
MeeVee offers a personalized online TV guide that allows users to curate their viewing experience based on their favorite actors, genres, or specific interests. By selecting preferences, users receive tailored recommendations for upcoming programming, which the guide continuously updates until interests are modified. The platform provides detailed information, including local television schedules, show summaries, episode trailers, ratings, and cast details, all at no cost. Additionally, MeeVee features a widget, known as the MeeVee Guide, which can be integrated into other websites, enabling visitors to view personalized TV listings. This service aims to simplify how individuals discover and enjoy television content, moving away from traditional universal grids to a more customized viewing experience.
MeeVee offers a personalized online TV guide that allows users to curate their viewing experience based on their favorite actors, genres, or specific interests. By selecting preferences, users receive tailored recommendations for upcoming programming, which the guide continuously updates until interests are modified. The platform provides detailed information, including local television schedules, show summaries, episode trailers, ratings, and cast details, all at no cost. Additionally, MeeVee features a widget, known as the MeeVee Guide, which can be integrated into other websites, enabling visitors to view personalized TV listings. This service aims to simplify how individuals discover and enjoy television content, moving away from traditional universal grids to a more customized viewing experience.
Fortinet is a cybersecurity company that specializes in network security appliances, including firewalls and security gateways. Its product offerings encompass network security, cloud security, zero-trust access, and security operations, catering to enterprises of all sizes, managed service providers, and telecommunications carriers. The company emphasizes delivering robust network, content, and application security while aiming to reduce total cost of ownership for its clients. Fortinet primarily generates revenue through subscription sales and support services, boasting a customer base of over 700,000 worldwide. Its solutions are designed to be flexible and scalable, facilitating expansion as organizational needs evolve.
Fortinet is a cybersecurity company that specializes in network security appliances, including firewalls and security gateways. Its product offerings encompass network security, cloud security, zero-trust access, and security operations, catering to enterprises of all sizes, managed service providers, and telecommunications carriers. The company emphasizes delivering robust network, content, and application security while aiming to reduce total cost of ownership for its clients. Fortinet primarily generates revenue through subscription sales and support services, boasting a customer base of over 700,000 worldwide. Its solutions are designed to be flexible and scalable, facilitating expansion as organizational needs evolve.
As of June 11, 2007, BroadWare Technologies, Inc. was acquired by Cisco Systems, Inc. BroadWare Technologies, Inc., a network video systems company, engages in the development and delivery of platforms and end-to-end browser-based solutions for collecting, recording, routing, and managing live and archived surveillance video. It offers Media Platform, a suite of server-based technologies for management, distribution, and storage of video surveillance data in a network environment; and Application Server, which enables users to determine levels of authority for viewing cameras, creating or viewing archives, and controlling movable cameras. The company offers Command Server, a digital matrix switch that allows each operator and intelligent application to control the video being displayed on various monitors; and Media Server that enables distribution, archiving, and management of video feeds. In addition, BroadWare Technologies provides specialty professional services, education and training, and support services. The company provides its products for use in applications, such as military bases, unmanned vehicles, embassies, corrections, border control, perimeter montoring, law enforcement, airports and seaports, homeland security, traffic montoring, and public infrastructure montoring, as well as corporate security, retail, public transit systems, gaming, health care, colleges and universities monitoring, petro-chemical, utlitites, and financial services. It serves airports and seaports, transportation systems, and various federal agencies and military branches. The company, formerly known as Graham Technology Solutions, was founded in 1995 and is headquartered in Santa Clara, California.
Fortinet is a cybersecurity company that specializes in network security appliances, including firewalls and security gateways. Its product offerings encompass network security, cloud security, zero-trust access, and security operations, catering to enterprises of all sizes, managed service providers, and telecommunications carriers. The company emphasizes delivering robust network, content, and application security while aiming to reduce total cost of ownership for its clients. Fortinet primarily generates revenue through subscription sales and support services, boasting a customer base of over 700,000 worldwide. Its solutions are designed to be flexible and scalable, facilitating expansion as organizational needs evolve.
Oplus Technologies Ltd., a fabless semiconductor company, designs, develops, and markets integrated circuit display processors and software solutions for the digital display market. It offers multimedia display and video processors for flat panel plasma and LCD displays, TVs, projection systems, LCD monitors, and digital display applications. The company also provides system-on-chip solutions. It serves consumer electronics companies and display device manufacturers in Israel and internationally. Oplus Technologies Ltd. was founded in 1993 and is headquartered in Yokneam, Israel.
SourceGate Systems, developers of a managed service which enables ISPs to create new advertising-based revenue streams.
Intraspect Software specializes in inter-enterprise solutions that enhance collaborative business processes. Founded in 1995 and acquired by Vignette in 2003, the company offers portal collaboration tools that allow users to create shared communities focused on strategic accounts, products, and business processes. Its flagship product, Intraspect 5.5, features architectural improvements suited for inter-enterprise deployments, while C-mail Services facilitate user interaction with Intraspect solutions through effective communication channels. The company’s software is particularly beneficial for industries such as financial services and high technology, enabling cross-functional teams to collaborate and communicate effectively with customers, suppliers, and partners across various organizational and geographic boundaries.